drugset / Trial / NCT05058040

A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)

NCT05058040 ↗

Phase 4 Active not recruiting 2500 enrolled Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

A clinical study to evaluate the long-term safety of Sodium Oligomannate Capsules (GV-971)

Timeline

Start
2021-06-02
Primary completion
2025-01
Completion
2025-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Sodium Oligomannate Oligonucleotide (other) 450 mg Oral

Indications